Skip to main content
SpringerLink
Log in

Natriuretic Peptides: Physiology for the Clinician

  • Chapter
  • First Online:
Cardiac Biomarkers

  • 1198 Accesses

Abstract

Natriuretic peptides (NPs) are a family of hormones that have significant cardiorenal properties. As an important component of blood pressure homeostasis in humans, NPs are potent vasodilatory hormones that mediate diuresis, natriuresis and cardiac remodeling (Levin et al., N Engl J Med 339(5):321–328, 1998). Neurohormonal signaling plays an essential role in cardiovascular disease. Whereas antagonism of the renin-angiotensin-aldosterone pathway, a mediator of pro-vascocontriction, leads to improved outcomes in heart failure, the potentiation of the NPs leads to vasodilation and improved cardiac remodeling. Therefore, NPs have been investigated both as a biomarker for cardiovascular disease as well as a potential treatment agent.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339(5):321–8. doi:10.1056/NEJM199807303390507.

    Article  CAS  PubMed  Google Scholar 

  2. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. J Hypertens. 1992;10(10):1111–4.

    Article  CAS  PubMed  Google Scholar 

  3. Potter LR, Hunter T. Guanylyl cyclase-linked natriuretic peptide receptors: structure and regulation. J Biol Chem. 2001;276(9):6057–60. doi:10.1074/jbc.R000033200.

    Article  CAS  PubMed  Google Scholar 

  4. Rubattu S, Sciarretta S, Morriello A, Calvieri C, Battistoni A, Volpe M. NPR-C: a component of the natriuretic peptide family with implications in human diseases. J Mol Med (Berl). 2010;88(9):889–97. doi:10.1007/s00109-010-0641-2.

    Article  CAS  Google Scholar 

  5. Hutchinson HG, Trindade PT, Cunanan DB, Wu CF, Pratt RE. Mechanisms of natriuretic-peptide-induced growth inhibition of vascular smooth muscle cells. Cardiovasc Res. 1997;35(1):158–67.

    Article  CAS  PubMed  Google Scholar 

  6. Pandey KN. Biology of natriuretic peptides and their receptors. Peptides. 2005;26(6):901–32. doi:10.1016/j.peptides.2004.09.024.

    Article  CAS  PubMed  Google Scholar 

  7. Gupta DK, Wang TJ. Natriuretic peptides and cardiometabolic health. Circ J. 2015;79(8):1647–55. doi:10.1253/circj.CJ-15-0589.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ogawa Y, Tamura N, Chusho H, Nakao K. Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart. Can J Physiol Pharmacol. 2001;79(8):723–9.

    Article  CAS  PubMed  Google Scholar 

  9. Mori M, Yamanashi Y, Kobayashi K, Sakamoto A. Atrial natriuretic peptide alleviates cardiovascular and metabolic disorders in a rat endotoxemia model: a possible role for its anti-inflammatory properties. J Nippon Med Sch. 2010;77(6):296–305.

    Article  CAS  PubMed  Google Scholar 

  10. Sengenes C, Zakaroff-Girard A, Moulin A, Berlan M, Bouloumie A, Lafontan M, et al. Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity. Am J Physiol Regul Integr Comp Physiol. 2002;283(1):R257–65. doi:10.1152/ajpregu.00453.2001.

    Article  CAS  PubMed  Google Scholar 

  11. Belluardo P, Cataliotti A, Bonaiuto L, Giuffre E, Maugeri E, Noto P, et al. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2006;291(4):H1529–35. doi:10.1152/ajpheart.00107.2006.

    Article  CAS  PubMed  Google Scholar 

  12. Chun TH, Itoh H, Ogawa Y, Tamura N, Takaya K, Igaki T, et al. Shear stress augments expression of C-type natriuretic peptide and adrenomedullin. Hypertension. 1997;29(6):1296–302.

    Article  CAS  PubMed  Google Scholar 

  13. Chen HH. Heart failure: a state of brain natriuretic peptide deficiency or resistance or both! J Am Coll Cardiol. 2007;49(10):1089–91. doi:10.1016/j.jacc.2006.12.013.

    Article  PubMed  Google Scholar 

  14. Semenov AG, Tamm NN, Seferian KR, Postnikov AB, Karpova NS, Serebryanaya DV, et al. Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin Chem. 2010;56(7):1166–76. doi:10.1373/clinchem.2010.143883.

    Article  PubMed  Google Scholar 

  15. Ichiki T, Huntley BK, Burnett Jr JC. BNP molecular forms and processing by the cardiac serine protease corin. Adv Clin Chem. 2013;61:1–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, Redfield MM, et al. Immunoreactivity and guanosine 3′,5′-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension. 2007;49(5):1114–9. doi:10.1161/HYPERTENSIONAHA.106.081083.

    Article  CAS  PubMed  Google Scholar 

  17. Wu F, Yan W, Pan J, Morser J, Wu Q. Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes. J Biol Chem. 2002;277(19):16900–5. doi:10.1074/jbc.M201503200.

    Article  CAS  PubMed  Google Scholar 

  18. Wu Q, Xu-Cai YO, Chen S, Wang W. Corin: new insights into the natriuretic peptide system. Kidney Int. 2009;75(2):142–6. doi:10.1038/ki.2008.418.

    Article  CAS  PubMed  Google Scholar 

  19. Rame JE, Tam SW, McNamara D, Worcel M, Sabolinski ML, Wu AH, et al. Dysfunctional corin i555(p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: results from the Genetic Risk Assessment in Heart Failure substudy. Circ Heart Fail. 2009;2(6):541–8. doi:10.1161/CIRCHEARTFAILURE.109.866822.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Luckenbill KN, Christenson RH, Jaffe AS, Mair J, Ordonez-Llanos J, Pagani F, et al. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin Chem. 2008;54(3):619–21. doi:10.1373/clinchem.2007.097998.

    Article  CAS  PubMed  Google Scholar 

  21. Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail. 2003;5(5):599–606.

    Article  CAS  PubMed  Google Scholar 

  22. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett Jr JC. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40(5):976–82.

    Article  CAS  PubMed  Google Scholar 

  23. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106(4):416–22.

    Article  PubMed  Google Scholar 

  24. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27(3):330–7. doi:10.1093/eurheartj/ehi631.

    Article  CAS  PubMed  Google Scholar 

  25. O’Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32–43. doi:10.1056/NEJMoa1100171.

    Article  PubMed  Google Scholar 

  26. Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013;310(23):2533–43. doi:10.1001/jama.2013.282190.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Yancy CW, Krum H, Massie BM, Silver MA, Stevenson LW, Cheng M, et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. Circ Heart Fail. 2008;1(1):9–16. doi:10.1161/CIRCHEARTFAILURE.108.767483.

    Article  CAS  PubMed  Google Scholar 

  28. Chen HH, Redfield MM, Nordstrom LJ, Horton DP, Burnett Jr JC. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail. 2004;10(2):115–9.

    Article  CAS  PubMed  Google Scholar 

  29. Hata N, Seino Y, Tsutamoto T, Hiramitsu S, Kaneko N, Yoshikawa T, et al. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J. 2008;72(11):1787–93.

    Article  CAS  PubMed  Google Scholar 

  30. Nomura F, Kurobe N, Mori Y, Hikita A, Kawai M, Suwa M, et al. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study. Circ J. 2008;72(11):1777–86.

    Article  CAS  PubMed  Google Scholar 

  31. Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J. 2006;27(23):2823–32. doi:10.1093/eurheartj/ehl337.

    Article  CAS  PubMed  Google Scholar 

  32. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. doi:10.1056/NEJMoa1409077.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN, USA

    Siu-Hin Wan MD & Horng H. Chen MB, BCh

Authors
  1. Siu-Hin Wan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Horng H. Chen MB, BCh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Siu-Hin Wan MD or Horng H. Chen MB, BCh .

Editor information

Editors and Affiliations

  1. Division of Cardiovascular Medicine, University of California San Diego Division of Cardiovascular Medicine, La Jolla, California, USA

    Alan S. Maisel

  2. Cardiology Department, Mayo Clinic Cardiology Department, ROCHESTER, Minnesota, USA

    Allan S. Jaffe

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Wan, SH., Chen, H.H. (2016). Natriuretic Peptides: Physiology for the Clinician. In: Maisel, A., Jaffe, A. (eds) Cardiac Biomarkers. Springer, Cham. https://doi.org/10.1007/978-3-319-42982-3_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42982-3_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42980-9

  • Online ISBN: 978-3-319-42982-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation